62 related articles for article (PubMed ID: 1624733)
21. [Significance and effects of intraperitoneal cisplatin administration for ovarian cancer].
Shimizu A; Ookubo K; Hasegawa J; Endoh T; Fujiwara O; Yoda A; Okuyama D; Narabayashi A; Kimura T; Takahashi J; Notake Y
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1801-5. PubMed ID: 10560398
[TBL] [Abstract][Full Text] [Related]
22. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
23. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
Braly PS; Berek JS; Blessing JA; Homesley HD; Averette H
Gynecol Oncol; 1995 Feb; 56(2):164-8. PubMed ID: 7896179
[TBL] [Abstract][Full Text] [Related]
24. Life-threatening hypocalcemia and hypomagnesemia associated with cisplatin chemotherapy.
Gonzalez C; Villasanta U
Obstet Gynecol; 1982 Jun; 59(6):732-4. PubMed ID: 7200596
[No Abstract] [Full Text] [Related]
25. Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma.
Sakuragi N; Nakajima A; Nomura E; Noro N; Yamada H; Yamamoto R; Fujimoto S
Gynecol Oncol; 2000 Dec; 79(3):420-3. PubMed ID: 11104613
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
[TBL] [Abstract][Full Text] [Related]
27. Intraperitoneal cis-platinum as salvage therapy for refractory epithelial ovarian cancer.
Hacker NF; Berek JS; Pretorius RG; Zuckerman J; Eisenkop S; Lagasse LD
Obstet Gynecol; 1987 Nov; 70(5):759-64. PubMed ID: 3658287
[TBL] [Abstract][Full Text] [Related]
28. Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer.
Lan C; Li Y; Liu J
Gynecol Oncol; 2009 Jul; 114(1):42-7. PubMed ID: 19398124
[TBL] [Abstract][Full Text] [Related]
29. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
[No Abstract] [Full Text] [Related]
30. [Central neurotoxic side effects following cisplatin therapy].
Schindler C; Richter R; Kühndel K
Zentralbl Gynakol; 1987; 109(1):60-3. PubMed ID: 3577464
[TBL] [Abstract][Full Text] [Related]
31. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin and cyclophosphamide in early epithelial ovarian carcinoma.
Chiara S; Conte PF; Bruzzone M; Falcone A; Sertoli MR; Carnino F; Mossetti C; Iura R; Durando C; Guercio E
Chemioterapia; 1987 Oct; 6(5):380-3. PubMed ID: 3427698
[TBL] [Abstract][Full Text] [Related]
33. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
34. Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy.
Tarraza HM; Boyce CR; Smith WG; Jones MA
Gynecol Oncol; 1993 Sep; 50(3):287-90. PubMed ID: 8406188
[TBL] [Abstract][Full Text] [Related]
35. [Results of cisplatin-based polychemotherapy and analysis of prognostic factors in ovarian cancer. Apropos of 106 cases].
Maloisel F; Dufour P; Bergerat JP; Bellocq JP; Duclos B; Boilletot A; Herbrecht R; Dellenbach P; Renaud R; Ritter P
Bull Cancer; 1989; 76(10):1083-93. PubMed ID: 2635636
[TBL] [Abstract][Full Text] [Related]
36. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.
Landrum LM; Gold MA; Moore KN; Myers TK; McMeekin DS; Walker JL
Gynecol Oncol; 2008 Feb; 108(2):342-7. PubMed ID: 17988721
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
38. Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer.
Hensley ML; Lebeau D; Leon LF; Venkatraman E; Waltzman R; Sabbatini P; Almadrones L; Chi D; Spriggs D
Gynecol Oncol; 2001 Jun; 81(3):485-9. PubMed ID: 11371143
[TBL] [Abstract][Full Text] [Related]
39. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
Fanning J; Hilgers RD
Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
[TBL] [Abstract][Full Text] [Related]
40. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891.
Rogers PC; Olson TA; Cullen JW; Billmire DF; Marina N; Rescorla F; Davis MM; London WB; Lauer SJ; Giller RH; Cushing B; ;
J Clin Oncol; 2004 Sep; 22(17):3563-9. PubMed ID: 15337806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]